Abstract
2067 Background: BEV is approved for the treatment of recurrent glioblastoma pts, but there is a lack of effective therapies once a tumor recurs on BEV. CTO, an oral inhibitor of non-voltage-depend...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have